Baricitinib reduces mortality of hospitalised COVID patients by 46 percent
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk…
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk of death in hospitalised COVID-19 patients receiving invasive mechanical ventilation or ECMO.